Abstract

Omnicell will report fourth-quarter results on February 05, 2026 Pre-Market; the preview synthesizes last quarter’s actuals and this quarter’s forecasts, along with recent institutional views, to outline revenue, gross profit margin, net margin, and adjusted EPS expectations.

Market Forecast

The market’s current consensus, aligned with company guidance embedded in forecasts, points to fourth-quarter revenue at $313.39 million, with estimated year-over-year growth of 4.60%, EBIT at $27.53 million with estimated year-over-year growth of 5.19%, and adjusted EPS at $0.50 with estimated year-over-year decline of 14.44%. Forecasts do not explicitly state gross margin or net margin for the current quarter; last quarter context suggests gross margin resilience near the low-40% range and a low single-digit net margin, while adjusted EPS trends reflect near-term investment and mix effects. Omnicell’s main business centers on Product and Service offerings, with Product forecast to continue leading overall revenue scale and Service underpinning recurring performance and customer retention. The most promising segment appears to be Service due to stickier contracts and installed-base monetization; last quarter Service revenue was $133.13 million with solid year-over-year momentum implied by total revenue growth of 9.99%.

Last Quarter Review

Omnicell reported prior-quarter revenue of $310.63 million, a gross profit margin of 43.30%, GAAP net profit attributable to the parent company of $5.46 million, a net profit margin of 1.76%, and adjusted EPS of $0.51, with year-over-year adjusted EPS change of -8.93% and revenue growth of 9.99%. A notable highlight was stronger-than-expected execution against consensus, with revenue of $310.63 million exceeding estimates by $15.04 million and EBIT of $27.44 million surpassing estimates by $9.70 million. Main business trends showed Product revenue at $177.50 million and Service revenue at $133.13 million, underscoring a balanced mix and supportive recurring revenue base.

Current Quarter Outlook

Main Business: Product and Service Mix

The Product segment remains the largest revenue contributor, supported by capital equipment demand and installed-base refreshes. While macro procurement cycles in healthcare can elongate decision timelines, the momentum from last quarter suggests continued shipment cadence into the fourth quarter. Pricing discipline and cost controls are likely to support gross margin stability near the low-40% range, though mix shifts toward Service could temper short-term Product margins. The Service segment provides recurring revenue streams through maintenance, software subscriptions, and performance services that deepen customer relationships; this inherently stabilizes cash flow and reduces cyclicality compared with purely capital-heavy product sales.

Most Promising Business: Service Recurrence and Installed-Base Monetization

Service is positioned to be the growth anchor for the quarter, benefiting from contracted revenue, high renewal rates, and incremental upsell opportunities into existing hospital systems. The installed base accumulated through years of product deployments creates a pathway for software and maintenance expansions, often requiring minimal selling costs relative to new hardware installations. With last quarter Service revenue at $133.13 million, the trajectory is favorable as Omnicell enhances offerings tied to analytics, automation enhancements, and workflow optimization, each contributing to higher-value services. This recurring dynamic can mitigate earnings volatility and fortify margin resilience, especially when capital budgets face scrutiny across healthcare providers.

Stock Price Drivers: Earnings Quality, Margin Mix, and Guidance Precision

Stock price sensitivity this quarter will hinge on the quality of earnings relative to consensus: delivery against the $313.39 million revenue estimate and the $0.50 adjusted EPS forecast will be closely examined. Margin mix between Product and Service will be crucial; incremental growth in Service tends to provide steadier margin visibility but may cap near-term EPS upside if Product mix is lighter than anticipated. The precision and tone of guidance—especially commentary on procurement pipeline, cost initiatives, and the trajectory of EBIT growth at 5.19% year-over-year—will influence investor conviction. Any evidence of accelerated adoption within key customer cohorts or better-than-expected operating leverage could prompt positive revisions, while cautionary signals on hospital budget constraints or deferred installations could pressure the stock.

Analyst Opinions

The prevailing institutional view in the recent period is bullish. Craig-Hallum reiterated a Buy rating on Omnicell, reflecting confidence in execution and the durability of the Service-led model within the installed base. Their stance aligns with an outlook that sees fourth-quarter revenue rising by 4.60% year-over-year to $313.39 million and EBIT expanding by 5.19% year-over-year to $27.53 million, while adjusted EPS is forecast at $0.50, acknowledging transitory mix and investment effects. The Buy thesis is underpinned by expectations for stable low-40% gross margins and improving operational efficiency, with recurring services cushioning potential variability in capital sales. Market participants will monitor whether Omnicell can exceed the revenue and EBIT benchmarks, which would validate the bullish positioning and possibly catalyze fresh upgrades or target raises, particularly if management articulates a clear path for sustained Service growth and operating leverage into the next fiscal year.